A next-gen PPAR activator making waves in the SARM research community.
GW-0742 is a SARM that is more commonly categorized as an agonist of selective peroxisome proliferator-activated receptors (PPARs). PPARs have been shown to be involved in the metabolism of lipids and carbohydrates as well as playing a role in the regulation of metabolic homeostasis and reduction of inflammation.
In a fascinating study by Niu et. Al, male Wister rats that weighed between 260 and 280 grams were given a high fructose diet to see the effect GW-0742 has on blood glucose levels and levels of insulin resistance.
The rats in this study were fed a 60% fructose-rich food that induced type 2 diabetes and insulin resistance, over the span of two months. During this time period, both plasma glucose and plasma insulin levels rose considerably. From there, the levels of glucose and insulin sensitivity were used to measure the efficacy of supplementation with GW-0742. Following supplementation, it was found that by injecting rats with GW-0742 when in a metabolically challenged state. This resulted in increased insulin sensitivity and glucose levels lowered drastically (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610778/).
Similarly, in a study conducted by Constantin et. Al, male Wister rats were used to test the effects of GW-0742 on fuel utilization in the body.
The rats were given either a vehicle or active GW-0742 over the course of 6 days at doses of either 5 mg/kg or 100 mg/kg. After dosing the mice with GW-0742, it was shown that over the course of intake, fuel pathways in the body shifted from using high amounts of carbohydrates to using lipid oxidation due to increased protein expression as well as increased PDK mRNA